Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Management of AF includes rate control, rhythm control if necessary, prevention of thromboembolic events, and treatment of the underlying disease. Rate control is usually achieved by pharmacological suppression of calcium currents or by applying β-blockers or digitalis compounds. In contrast, the number of compounds available for rhythm control is still limited. Class Ic agents increase mortality in patients with structural heart disease, and amiodarone harbors an extensive side effect profile despite its efficacy in maintaining sinus rhythm. Furthermore, rhythm control by these compounds has not been shown to reduce patient mortality. Dronedarone is a new anti-arrhythmic drug that has been developed to provide rhythm and rate control in AF patients with fewer side effects compared with amiodarone. This review primarily focuses on clinical trials evaluating efficacy and safety of the novel drug. Conclusions from these studies are critically reviewed, and recommendations for clinical practice are discussed. Dronedarone significantly reduced the incidence of hospitalization due to cardiovascular events or death in high-risk patients with atrial fibrillation (ATHENA trial). However, dronedarone was less efficient than amiodarone in maintaining normal sinus rhythm (DIONYSOS trial) and is contraindicated in severe or deteriorating heart failure (ANDROMEDA trial). In summary, dronedarone represents a valuable addition to the limited spectrum of antiarrhythmic drugs and is currently recommended in patients with paroxysmal and persistent AF to achieve rate and rhythm control, excluding cases of severe or unstable congestive heart failure.
Department of Cardiology, Medical University Hospital, Heidelberg, Germany.
Patrick A
PA
Schweizer
Rüdiger
R
Becker
Hugo A
HA
Katus
Dierk
D
Thomas
D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D000077764:Dronedarone; D006333:Heart Failure / Q000150:complications; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone
J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605
20384650
J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
12548079
Br J Clin Pharmacol. 2007 Dec;64(6):785-91
17662087
N Engl J Med. 2007 Sep 6;357(10):987-99
17804843
Lancet. 2000 Nov 25;356(9244):1789-94
11117910
Consult Pharm. 2010 Sep;25(9):555-69
20876046
Am J Ther. 2006 Jul-Aug;13(4):315-9
16858166
Eur J Pharmacol. 2004 Aug 2;496(1-3):119-27
15288583
J Am Coll Cardiol. 2006 Aug 15;48(4):854-906
16904574
Am J Med. 2002 Oct 1;113(5):359-64
12401529
Am J Cardiol. 2009 Dec 1;104(11):1534-9
19932788
J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95
19744618
Cardiovasc Drug Rev. 2005 Fall;23(3):217-30
16252015
Am Heart J. 2008 Sep;156(3):527.e1-9
18760136
Circulation. 2009 Sep 29;120(13):1174-80
19752319
Circ Res. 1977 Jul;41(1):9-18
862147
Vasc Health Risk Manag. 2010 Aug 09;6:517-23
20730068
Lancet. 2006 Jan 21;367(9506):262-72
16427496
N Engl J Med. 2008 Jun 19;358(25):2678-87
18565860
Heart Rhythm. 2004 Nov;1(5):531-7
15851214
Circ Arrhythm Electrophysiol. 2008 Apr;1(1):62-73
19808395
Ann Intern Med. 2007 Jun 19;146(12):857-67
17577005
Circulation. 1998 Sep 8;98(10):946-52
9737513
Vasc Health Risk Manag. 2009;5:635-42
19688104
Eur Heart J. 2003 Aug;24(16):1481-7
12919771
N Engl J Med. 2009 Feb 12;360(7):668-78
19213680
Nat Rev Drug Discov. 2006 Dec;5(12):1034-49
17139288
Lancet. 2010 Apr 3;375(9721):1212-23
20334907
Nature. 2002 Jan 10;415(6868):219-26
11805846
Neuroepidemiology. 2003 Mar-Apr;22(2):118-23
12629277
N Engl J Med. 1991 Mar 21;324(12):781-8
1900101
Br J Pharmacol. 2003 Nov;140(5):996-1002
14517175
Circulation. 2003 Jun 17;107(23):2920-5
12771006
N Engl J Med. 2002 Dec 5;347(23):1834-40
12466507
Eur J Pharmacol. 1995 Jun 6;279(1):25-32
7556379
JAMA. 2001 May 9;285(18):2370-5
11343485
Circ Res. 1993 Mar;72(3):631-50
8431989
Europace. 2006 Sep;8(9):651-745
16987906
Curr Vasc Pharmacol. 2007 Jul;5(3):185-95
17627562
J Am Coll Cardiol. 2003 May 21;41(10):1690-6
12767648
Pharmacotherapy. 2010 Sep;30(9):904-15
20795846
Nature. 1992 Jan 23;355(6358):349-51
1731248
Stroke. 1991 Aug;22(8):983-8
1866765
Eur Heart J. 2010 Oct;31(19):2369-429
20802247
Clin Pharmacol Ther. 2004 Apr;75(4):342-51
15060512
Europace. 2011 Aug;13(8):1118-26
21576129
Europace. 2005 Sep;7 Suppl 2:10-20
16102499
N Engl J Med. 2002 Dec 5;347(23):1825-33
12466506
J Cardiovasc Pharmacol. 2002 May;39(5):677-84
11973411
Mayo Clin Proc. 2009 Mar;84(3):234-42
19252110